[go: up one dir, main page]

WO2024163349A3 - Kits and methods useful for prognosing, diagnosing, and treating prostate cancer - Google Patents

Kits and methods useful for prognosing, diagnosing, and treating prostate cancer Download PDF

Info

Publication number
WO2024163349A3
WO2024163349A3 PCT/US2024/013358 US2024013358W WO2024163349A3 WO 2024163349 A3 WO2024163349 A3 WO 2024163349A3 US 2024013358 W US2024013358 W US 2024013358W WO 2024163349 A3 WO2024163349 A3 WO 2024163349A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosing
diagnosing
kits
prostate cancer
treating prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/013358
Other languages
French (fr)
Other versions
WO2024163349A2 (en
Inventor
Arul M. Chinnaiyan
Jeffrey J. TOSOIAN
Yuping Zhang
Lanbo XIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Priority to AU2024214806A priority Critical patent/AU2024214806A1/en
Priority to EP24750790.8A priority patent/EP4658817A2/en
Priority to CN202480009773.8A priority patent/CN120917152A/en
Priority to KR1020257028740A priority patent/KR20250141769A/en
Publication of WO2024163349A2 publication Critical patent/WO2024163349A2/en
Publication of WO2024163349A3 publication Critical patent/WO2024163349A3/en
Priority to MX2025008640A priority patent/MX2025008640A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Databases & Information Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and/or treating prostate cancer based on expression levels of cancer markers.
PCT/US2024/013358 2023-01-30 2024-01-29 Kits and methods useful for prognosing, diagnosing, and treating prostate cancer Ceased WO2024163349A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2024214806A AU2024214806A1 (en) 2023-01-30 2024-01-29 Kits and methods useful for prognosing, diagnosing, and treating prostate cancer
EP24750790.8A EP4658817A2 (en) 2023-01-30 2024-01-29 Kits and methods useful for prognosing, diagnosing, and treating prostate cancer
CN202480009773.8A CN120917152A (en) 2023-01-30 2024-01-29 Kits and methods for the prognosis, diagnosis, and treatment of prostate cancer
KR1020257028740A KR20250141769A (en) 2023-01-30 2024-01-29 Kits and methods useful for prognosing, diagnosing, and treating prostate cancer
MX2025008640A MX2025008640A (en) 2023-01-30 2025-07-24 EQUIPMENT AND METHODS FOR PROGNOSIS, DIAGNOSTICS AND TREATMENT OF PROSTATE CANCER

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363442045P 2023-01-30 2023-01-30
US63/442,045 2023-01-30
US202363446596P 2023-02-17 2023-02-17
US63/446,596 2023-02-17

Publications (2)

Publication Number Publication Date
WO2024163349A2 WO2024163349A2 (en) 2024-08-08
WO2024163349A3 true WO2024163349A3 (en) 2024-09-26

Family

ID=92147517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/013358 Ceased WO2024163349A2 (en) 2023-01-30 2024-01-29 Kits and methods useful for prognosing, diagnosing, and treating prostate cancer

Country Status (7)

Country Link
US (1) US20250034648A1 (en)
EP (1) EP4658817A2 (en)
KR (1) KR20250141769A (en)
CN (1) CN120917152A (en)
AU (1) AU2024214806A1 (en)
MX (1) MX2025008640A (en)
WO (1) WO2024163349A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230016456A1 (en) * 2010-11-19 2023-01-19 The Regents Of The University Of Michigan ncRNA AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230016456A1 (en) * 2010-11-19 2023-01-19 The Regents Of The University Of Michigan ncRNA AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURSANO M. C., CONTEDUCA V., SCARPI E., GURIOLI G., CASADEI C., GARGIULO S., ALTAVILLA A., LOLLI C., VINCENZI B., TONINI G., SANTI: "Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, US, vol. 12, no. 1, US , XP093218627, ISSN: 2045-2322, DOI: 10.1038/s41598-022-10751-6 *

Also Published As

Publication number Publication date
WO2024163349A2 (en) 2024-08-08
US20250034648A1 (en) 2025-01-30
CN120917152A (en) 2025-11-07
KR20250141769A (en) 2025-09-29
MX2025008640A (en) 2025-09-02
EP4658817A2 (en) 2025-12-10
AU2024214806A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
King et al. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2022109607A3 (en) Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment
Cheng et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MXPA03003281A (en) Non-invasive enzyme screen for tissue remodelling-associated conditions.
WO2007064776A3 (en) Markers for breast cancer
McTiernan et al. Improving outcomes after relapse in Ewing′ s sarcoma: analysis of 114 patients from a single institution
DE50311312D1 (en) METHOD FOR EXAMINING BODY FLUIDS ON CANCER CELLS AND CORRESPONDING ANALYSIS KITS
WO2021202666A3 (en) Genomic classifiers for prognosing and treating clinically aggressive luminal bladder cancer
WO2024163349A3 (en) Kits and methods useful for prognosing, diagnosing, and treating prostate cancer
Zach et al. Can we extend the indication for sentinel node biopsy in vulvar cancer? A nationwide feasibility study from Sweden
McHaffie et al. Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer
Kumagai et al. Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy
WO2004093646A3 (en) Prognosis, diagnosis and treatment of bone marrow derived stem cell associated cancer
WO2023230617A3 (en) Bladder cancer biomarkers and methods of use
WO2023158783A3 (en) Methods, compositions, and combinations for preventing or treating cancer recurrence
Hammerer et al. Prostatic biopsy after radiotherapy: when and how
WO2005113835A3 (en) Kits and methods for indentification, assessment, prevention and therapy of breast cancer
WO2021034975A3 (en) Protein panels for the early diagnosis/prognosis and treatment of aggressive prostate cancer
WO2024073476A3 (en) Compositions and methods for treating cancer by reducing the expression and/or activity of pla2g10
WO2024206869A3 (en) Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
Amiel et al. MP63-14 PRELIMINARY RESULTS OF FIRST-IN-HUMAN CRYOTHERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER
Forrest et al. Treatment Outcomes for Patients with Advanced Cervical Cancer Treated with V˙ GOG Protocol Compatible'Definitive Chemoradiotherapy and HDR Brachytherapy
Spencer et al. 1571: Adjuvant Intravesical Therapy and Improved Survival Among Elderly Patients with Superficial Bladder Cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24750790

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024214806

Country of ref document: AU

Ref document number: 823457

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/008640

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 823457

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2025543858

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202480009773.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2024214806

Country of ref document: AU

Date of ref document: 20240129

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025015360

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517080448

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: MX/A/2025/008640

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202517080448

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 202480009773.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2024750790

Country of ref document: EP